CRO: contract research organization. A company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis.
At NeoVentures, we do not consider ourselves as a (CRO). We approach what we do more as co-entrepreneurs with you. Clients come to us with problems that might be solved with aptamers. We discuss the project in depth under confidentiality and together we develop an aptamer selection and application strategy. Sometimes we tell clients that what they have envisioned is not possible yet with aptamers. There are many reasons for this, sometimes the limit of detection required is simply not possible given the nature of the target.
We have learned that some selection processes and targets do not work well. For example:
- Selection of aptamers for specific cells, especially prokaryotic cells, based on cell selection alone.
- We think that this is because there is an abundance of poor targets on the surface.
- We prefer to design selections with a double positive round for a known protein followed by selection on living cells.
- Lipids, fatty acids, molecules less than 300 Daltons are not good aptamer targets.
- We have tried selections against these targets and are not satisfied with the results.
- Peptides
- We have generally thought that selection of aptamers for peptides should work well, but we have been consistently disappointed with the results. We think the issue is the selection on the peptide. We are now modelling the structural flux of peptides with software like PEP-FOLD4, but proteins will always be better targets.
In terms of aptamer applications, we have confidence in systems like qPCR and fluorescent switches for diagnostics. In our experience, electrochemistry platforms with existing commercial chips are not ready for commercial applications. We are working together with solution providers to make this work better and improve the chip to chip variability.
Le Dr. Gregory Penner a suivi une formation académique qui mêlait une théorie très pratique en matière de sélection végétale à la biologie moléculaire. Il a utilisé cette combinaison de biologie et de mathématiques pour développer et diriger une équipe de recherche en biotechnologie céréalière au sein du gouvernement du Canada, puis en tant que leader mondial de la recherche chez Monsanto Inc. Il a été un leader d'opinion en développement d'aptamères à l'échelle mondiale au cours des vingt dernières années en tant que PDG et président de NeoVentures. Il a dirigé cette entreprise vers la stabilité financière sans investissement extérieur grâce à une approche intégrée de la découverte et de la commercialisation des aptamères. En 2015, il a co-fondé une deuxième entreprise, NeoNeuro à Paris en France, axée sur une approche innovante pour identifier les Aptamarkers pour les maladies complexes.
Connectez-vous avec le Dr. Penner sur LinkedIn ou pour les mises à jour de l'entreprise, suivez NeoVentures.
French 
English 
Spanish